The “synthetic lethality” concept has been effective in mammalian cells in tumor models with defective BRCA1 or BRCA2, which, as a consequence have defective HR [3] and are thus amenable to use of PARPi as a monotherapy [11]. Here, BRCA2 is linked to neoplasm.